Introduction: Lu-177 can be made with high specific activity and no other isotopes of lutetium present, referred to as “no carrier added” (nca) Lu-177. We have radiolabelled DOTA-conjugated peptide DOTA‐(Tyr3)‐octreotate (Auspep, Melb., AUS) with nca Lu-177 (“nca-LuTATE”) and used it in over 30 administrations in NETs patients.
Conference: 12th Annual ENETS Conference (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Professor Dale Bailey
Introduction: The kidney is a dose-limiting organ in [177Lu]-Dotatate PRRT (Lutate) and thus renal function is an important prescribing consideration for NET patients. The effect of baseline renal function on kidney absorbed dose is unclear.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Enid Eslick